ソン ヨンス   SON YONSU
  孫 瑛洙
   所属   関西医科大学  内科学第一講座
   職種   講師
論文種別 原著(症例報告除く)
言語種別 英語
査読の有無 査読あり
表題 Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study
掲載誌名 正式名:Rheumatology international
略  称:Rheumatol Int
ISSNコード:01728172
掲載区分国外
巻・号・頁 41(7),pp.1233-1241
著者・共著者 Maeda Y, Hirano T, Ebina K, Hara R, Hashimoto M, Yamamoto W, Murakami K, Kotani T, Hata K, Son Y, Amuro H, Onishi A, Jinno S, Katayama M, Kumanogoh A.
発行年月 2021/07
概要 OBJECTIVE: We aimed to investigate the efficacy of anti-IL-6 receptor antibody
(aIL-6) and other biologic disease-modifying antirheumatic drugs (bDMARDs), such
as TNF inhibitor and CTLA4-Ig in the treatment of rheumatoid arthritis (RA) in
patients with knee joint involvement.
METHODS: We retrospectively analyzed 1059 treatment courses of patients with RA
who visited our hospitals and were treated with bDMARDs. We categorized them
into two groups, with or without knee joint involvement. We investigated the
clinical disease activity index (CDAI) at baseline and 12 weeks after the
initiation of bDMARDs. We compared the improvement of the markers between aIL-6
and other bDMARDs.
RESULTS: Treatment with aIL-6 significantly increased ΔCDAI (n = 91, 15.4 ± 1.1;
mean ± SEM) in patients with knee joint involvement, compared to other bDMARDs
(n = 232, 11.0 ± 0.7) at 12 weeks (P = 0.006). Following the multivariate
analysis adjusted by the CDAI levels at baseline, age, gender, concomitant use
of methotrexate, and the first use of bDMARDs, ΔCDAI levels were significantly
higher in aIL-6, compared to other bDMARDs (P = 0.02). However, there was no
significant difference in ΔCDAI improvement between aIL-6 (n = 162, 5.9 ± 0.6)
and other bDMARDs (n = 573, 6.2 ± 0.4) in patients without swollen knee joints.
ΔCDAI levels were equally increased in patients with shoulder and elbow joint
involvement.
CONCLUSION: aIL-6 was more effective in the patients with RA and knee joint
involvement, compared to other bDMARDs.
DOI 10.1007/s00296-021-04862-y
PMID 33903963